Physician profile
David Lee Tinklepaugh
NPI 1982711586
$1,753.40
in general payments reported to CMS, 2019-2025
23 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $336 · 2021: $373 · 2022: $246 · 2023: $50.84 · 2024: $78.75 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $303.90 | 2020-2022 | |
| Abbvie INC. | $292.76 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $196.65 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $190.17 | 2019-2022 | |
| Emd Serono, INC. | $139.29 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $119.30 | 2025 | Wainua |
| Boston Scientific Corporation | $96.91 | 2021 | |
| Allergan, INC. | $66.45 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $36.53 | 2019 | |
| Averitas Pharma INC. | $34.30 | 2024 | Qutenza |
| Ucb, INC. | $28.72 | 2023 | |
| Grifols USA, LLC | $28.72 | 2019-2025 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $24.79 | 2025 | Hyqvia |
| Lilly USA, LLC | $24.58 | 2024 | Kisunla |
| Catalyst Pharmaceuticals, INC. | $23.00 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.42 | 2025 | |
| Amneal Pharmaceuticals LLC | $22.12 | 2023 | Lyvispah |
| Azurity Pharmaceuticals, INC. | $19.70 | 2025 | Horizant |
| Mallinckrodt Enterprises LLC | $19.45 | 2019 | |
| Amgen INC. | $18.74 | 2019 | |
| Biogen, INC. | $16.44 | 2019 | |
| Currax Pharmaceuticals LLC | $14.58 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.88 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tinklepaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.